Founder & COO

Xianhua Yi PhD. in Biophysics and Biochemistry from Massachusetts State University and a Postdoctoral Fellow in Cell Biology at Massachusetts General Hospital, Harvard Medical School. Dr. Yi worked at MomentaPharmaceuticals (now Johnson & Johnson) on the analysis and QC/QA of two very complex generic drugs, both of which were approved and marketed by the FDA without clinical validation based on detailed analytical data, a milestone in the history of pharmaceutical development in the US.

Dr. Yi has more than 10 years of experience in analytical and QC/QA work for antibody and ADC drugs, and as a colleague of Dr. MaoYin, he was involved in the development of two clinical advancement ADC drugs for a NASDAQ-listed ADC company.

Dr. Yi received complete training and extensive industrial experience in biophysics, biochemistry, cell biology and modern large molecule biologics analysis and quality control in the US. He is currently in charge of the company's operations at Puling Biopharma.